Sign up online today & collaborate
or click here to find out more
New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilars
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory is designed to accommodate the rising demand for the company’s BioOutsource brand specialized assay platforms in North America and facilitate the ongoing expansion of this unique service offering.
At the opening ceremony, Reinhardt Vogt, member of SSB’s Executive Committee, welcomed many representatives from the biotech industry and the local community to the new laboratory. In his opening speech, Reinhard Vogt stated: “Our new laboratory will offer customers the analytical expertise to help them accelerate entry into clinical phases. We chose Boston as the site for our laboratory because it is a premier biotech hub, enabling us to showcase our portfolio of bioanalytical and biosafety tests, as well as attract the best technical staff to continue our expansion here in the future.”
The purpose-built laboratory features state-of-the-art technology, such as biacore analytical instruments, and offers advanced analytical testing services. These include Antibody Dependent Cell Cytotoxicity (ADCC); Complement Dependent Cytotoxicity (CDC) and Surface Plasmon Resonance (SPR) assay platforms; as well as cell-based assays and enzyme-linked immunosorbent assays (ELISAs). SSB’s new laboratory, which covers approximately 9,000 sq. ft. (830 m2), will also provide GMP-compliant in vitro and PCR-based assays for the detection of adventitious agents. Staffed by bioanalytical experts, including 15 scientists, the new laboratory provides easy access for customers to visit and have face-to-face meetings to discuss technical questions.
Sartorius Stedim Biotech’s new bioanalytical lab at 245 First Street, Cambridge, Boston
Link for Download: http://microsite.sartorius.com/fileadmin/newsletter/BioOutsource/BioOutsource_Boston_Lab.jpg
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and earned sales revenue of 884.3 million euros in 2015.
Since 2015 part of Sartorius Stedim Biotech Group, BioOutsource provides contract testing services to the biopharmaceutical industry. Its core offering includes a comprehensive range of services to support the testing of biologics, vaccines & biosimilars throughout development and manufacture. The company is dedicated to providing innovative solutions and delivering excellent customer service. With an unparalleled combination of commercial, regulatory and technical knowledge, BioOutsource truly stands out as the industry’s preferred testing partner.
Senior Manager Corporate Communications,
Sartorius Corporate Administration GmbH